Target intelligence / Profile preview

ZNF528 antisense RNA 1 (ZNF528-AS1)

Target
ZNF528-AS1
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript, Other (not a protein-coding gene, not an enzyme, receptor, etc.)
01

Overview

ZNF528 antisense RNA 1 (ZNF528-AS1) is a human long non-coding RNA (lncRNA) classified as a natural antisense transcript relative to the ZNF528 gene.[9][6][3] Its functional role remains largely uncharacterized but antisense lncRNAs are generally involved in regulating gene expression at multiple molecular levels, such as replication, transcription, and translation.[9][6][8] Dysregulation of ZNF528-AS1 and other antisense lncRNAs in osteosarcoma and other cancers suggests important roles in tumor progression, metastasis, and therapy resistance.[6][9] ZNF528-AS1 has been identified as upregulated in osteosarcoma tissue and cell lines, supporting its utility as a candidate biomarker and as a potential therapeutic target for cancer research.[9][6] There are currently no known pharmacological agents targeting this RNA directly, and its role in diseases outside of cancer remains unclear, although GeneCards notes a nominal association with Cockayne Syndrome A, possibly by genomic proximity or regulatory influence.[7][9]

Other names
ZNF528-AS1ZNF528 antisense RNA 1
02

Mechanism of action

Not specified (no drugs targeting ZNF528-AS1 or clear mechanism described in literature)

03

Biological functions

Regulation of gene expression (including at transcriptional, splicing, and mRNA stability levels)Potential involvement in cell proliferation, metastasis, resistance to therapy (based on collective antisense lncRNA literature)
04

Disease associations

Cancer: Upregulated in osteosarcoma, potential biomarker and therapeutic targetOther: Associated (by literature inference) with processes relevant to tumor progression, although direct disease association for ZNF528-AS1 is limited; GeneCards nominally links to Cockayne Syndrome A (likely via antisense transcript relationships, rather than direct causality)
05

Biomarkers

Upregulated expression in osteosarcoma: Proposed as a potential biomarker for diagnosis and/or prognosis in osteosarcoma

Beyond the preview

Go deeper on ZNF528 antisense RNA 1 (ZNF528-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZNF528 antisense RNA 1 (ZNF528-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call